0001447362-21-000213.txt : 20210907 0001447362-21-000213.hdr.sgml : 20210907 20210907172611 ACCESSION NUMBER: 0001447362-21-000213 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210902 FILED AS OF DATE: 20210907 DATE AS OF CHANGE: 20210907 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Spiess Bernhard E. CENTRAL INDEX KEY: 0001782994 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38984 FILM NUMBER: 211240119 MAIL ADDRESS: STREET 1: C/O CASTLE BIOSCIENCES, INC. STREET 2: 820 S. FRIENDSWOOD DRIVE, SUITE 201 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLE BIOSCIENCES INC CENTRAL INDEX KEY: 0001447362 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770701774 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 BUSINESS PHONE: 866-788-9007 MAIL ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 4 1 wf-form4_163104995353264.xml FORM 4 X0306 4 2021-09-02 0 0001447362 CASTLE BIOSCIENCES INC CSTL 0001782994 Spiess Bernhard E. C/O CASTLE BIOSCIENCES, INC. 505 S. FRIENDSWOOD DRIVE, STE. 401 FRIENDSWOOD TX 77546 0 1 0 0 Chief Business Officer Common Stock 2021-09-02 4 M 0 8989 1.92 A 22551 D Common Stock 2021-09-02 4 M 0 6412 2.39 A 28963 D Common Stock 2021-09-02 4 S 0 8038 75.24 D 20925 D Common Stock 2021-09-02 4 S 0 5889 76.14 D 15036 D Common Stock 2021-09-02 4 S 0 1474 77.29 D 13562 D Stock option (right to buy) 1.92 2021-09-02 4 M 0 8989 0 D 2026-05-23 Common Stock 8989.0 5889 D Stock option (right to buy) 2.39 2021-09-02 4 M 0 6412 0 D 2028-05-09 Common Stock 6412.0 2304 D These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021. This transaction was executed in multiple trades at prices ranging from $74.59 to $75.58, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $75.60 to $76.45, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $76.70 to $77.63, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. 25% of the 169,592 shares originally subject to the option vested on May 2, 2017, and the remaining shares vested in 36 equal monthly installments thereafter. 25% of the 12,305 shares originally subject to the option vested on May 10, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Greg Acosta, Attorney-in-fact 2021-09-07